Search
p-tert-Butylphenol-formaldehyde resin (low molecular weight)
go.drugbank.com/drugs/DB14190Approvedp-tert-Butylphenol-formaldehyde resin is a widely used adhesive chemical used in a wide variety of commercially available products and a known dermatological sensitizer and allergen [A34290,A34291]. … Sensitivity to p-tert-Butylphenol-formaldehyde resin may be identified with a clinical patch test.
Azacitidine
go.drugbank.com/drugs/DB00928ApprovedInvestigationalAs an analogue of cytidine, it is able to incorporate into RNA and DNA, disrupting RNA metabolism and inhibiting protein and DNA synthesis. … [A1407] Due to its anti-neoplastic activity and its ability to inhibit methylation in replicating DNA, azacytidine has been used mainly used in the treatment of myelodysplastic syndromes (MDS) and acute
Synonyms: 4-amino-1-beta-D-ribofuranosyl-s-triazin-2(1H)-oneDasatinib
go.drugbank.com/drugs/DB01254ApprovedInvestigational[A11377,A33432] Dasatinib also inhibits a spectrum of kinases involved in cancer, including several SRC-family kinases. … Dasatinib is an orally available multikinase inhibitor indicated for the treatment of Philadelphia chromosome (Ph)-positive leukemias.
Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP1A2 Substrates with a Narrow Therapeutic IndexCorticotropin
go.drugbank.com/drugs/DB01285ApprovedInvestigationalVet approvedCorticotropin (ACTH or adrenocorticotropic hormone) is a polypeptide hormone produced and secreted by the pituitary gland. It is an important player in the hypothalamic-pituitary-adrenal axis.
Blinatumomab
go.drugbank.com/drugs/DB09052ApprovedInvestigational[A254836,L44311] CD3 is an antigen expressed on the surface of T-cells, while CD19 is mostly expressed on the surface of malignant B-cells. … Blinatumomab is a BiTE-class (bi-specific T-cell engager) constructed monoclonal antibody formed by the recombinant fusion of an anti-CD3 single-chain variable fragment (scFV) and an anti-CD19 scFV through
Norgestrel
go.drugbank.com/drugs/DB09389ApprovedNorgestrel is composed of a racemic mixture of two stereoisomers, dextronorgestrel and levonorgestrel. However, only the levorotary enantiomer ([levonorgestrel]) is biologically active.
Categories: Sex Hormones and Modulators of the Genital SystemAbemaciclib
go.drugbank.com/drugs/DB12001ApprovedInvestigationalAbemaciclib is an antitumor agent and dual inhibitor of cyclin-dependent kinases 4 (CDK4) and 6 (CDK6) that are involved in the cell cycle and promotion of cancer cell growth in case of unregulated activity … On September 28, 2017, FDA granted approval of abemaciclib treatment under the market name Verzenio for the treatment of HR-positive and HER2-negative advanced or metastatic breast cancer that has progressed
Categories: MATE 1 Substrates with a Narrow Therapeutic Index, P-glycoprotein substrates with a Narrow Therapeutic IndexLornoxicam
go.drugbank.com/drugs/DB06725ApprovedInvestigationalLornoxicam differs from other oxicam compounds in its potent inhibition of prostaglandin biosynthesis, a property that explains the particularly pronounced efficacy of the drug. … Lornoxicam (chlortenoxicam) is a new nonsteroidal anti-inflammatory drug (NSAID) of the oxicam class with analgesic, anti-inflammatory and antipyretic properties.
Tazobactam
go.drugbank.com/drugs/DB01606ApprovedInvestigationalIt is combined with [Piperacillin] and [Ceftolozane] for the treatment of a variety of bacterial infections. … Tazobactam is an antibiotic of the beta-lactamase inhibitor class that prevents the breakdown of other antibiotics by beta-lactamase enzyme producing organisms.
Mixtures: KABICTAM® POLVO LIOFILIZADO PARA RECONSTITUIR A SOLUCION INYECTABLE, PIPERACILINA 4G + TAZOBACTAM 0.5G POLVO ESTERIL PARA RECONSTITUIR A SOLUCION INYECTABLEConcizumab
go.drugbank.com/drugs/DB12820ApprovedInvestigationalConcizumab is a humanized IgG4 monoclonal antibody targeting the Kunitz-2 domain of tissue factor pathway inhibitor (TFPI), a key regulator of the coagulation cascade. … [L51998,L52043] In July 2025, its indication was expanded to include all patients with hemophilia A or B, regardless of the presence of inhibitors.[L53653]